Kurozumi et al. [18] pointed out that PR expression level is an independent prognostic factor for HR-positive and HER2-negative breast cancer patients, especially when Ki-67 expression level is between 10% and 30%, patients with PR < 20% have a worse prognosis. This evidence concerns the gene ERBB2 and breast carcinoma.